Skip to content
OpenCapital
Get started

Pacific Biosciences of California PACB Cash & Equivalents

Cash & Equivalents at other companies

Illumina logo
IlluminaILMN
$1.09B-2.2%
Revvity logo
RevvityRVTY
$861.47M-24.3%
Maravai LifeSciences Holdings, Inc. logo
Maravai LifeSciences Holdings, Inc.MRVI
$165.92M-41.8%
Agilent Technologies logo
Agilent TechnologiesA
$1.81B+21.5%
Thermo Fisher Scientific logo
Thermo Fisher ScientificTMO
$3.28B-21.4%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$124.85M-41.4%

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's cash & equivalents?
Pacific Biosciences of California (PACB) reported cash & equivalents of $57.86M in Q1 2026.
How has Pacific Biosciences of California's cash & equivalents changed year-over-year?
Pacific Biosciences of California's cash & equivalents decreased by 4.7% year-over-year, from $60.73M to $57.86M.
What is the long-term trend for Pacific Biosciences of California's cash & equivalents?
Over 5 years (2020 to 2025), Pacific Biosciences of California's cash & equivalents has grown at a -5.4% compound annual growth rate (CAGR), from $85.95M to $65.26M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.